With the expansion of vaccination programs,the policy of terminating nonpharmaceutical interventions for preventing the SARS-CoV-2 pandemic should become more flexible.The current study investigated the clinical and e...With the expansion of vaccination programs,the policy of terminating nonpharmaceutical interventions for preventing the SARS-CoV-2 pandemic should become more flexible.The current study investigated the clinical and economic outcomes of intervention policies combining nonpharmaceutical interventions and vaccination programs for dealing with the SARS-CoV-2 pandemic.An agent-based transmission model was adopted that describes how a SARS-CoV-2 virus spreads in the populations of China.The model inputs were derived from the literature and expert opinion.The following intervention policies were simulated:no intervention,strict nonpharmaceutical interventions,and nonpharmaceutical interventions for workplace,community,school and home gradually terminated by combining vaccination programs for specified age groups(vaccination age in years:20-60,20-70,20-80,≥20,≥10 and whole population).Cumulative infections and deaths in one calendar year,costs and quality-adjusted life years(QALYs)were measured.When the vaccination program was taken up in at least the≥20 years age group in all populations,nonpharmaceutical interventions for workplace and community settings could be gradually terminated because the cumulative number of infections was<100 per 100,000 persons.Further ending nonpharmaceutical interventions in school and home settings could not meet the target even when the vaccination program had been taken up in all populations.When cumulative deaths were used as the endpoint,nonpharmaceutical interventions in workplace,community and school settings could be gradually terminated.Vaccine efficacy and coverage have substantial impacts.Terminating nonpharmaceutical interventions in workplace settings could produce the lowest cost when vaccination programs are taken up at least in the≥10 years age group;this method dominates most intervention strategies due to its lower costs and higher QALYs.According to our findings,nonpharmaceutical interventions might be gradually terminated in Chinese settings.展开更多
Dear Editor,Liver cancer is the third leading cause of cancer deaths worldwide and accounted for 8.9%of all neoplasms,as shown by the Global Burden of Disease Study 2017[1].Hepatocellular carcinoma(HCC)comprises 75%-8...Dear Editor,Liver cancer is the third leading cause of cancer deaths worldwide and accounted for 8.9%of all neoplasms,as shown by the Global Burden of Disease Study 2017[1].Hepatocellular carcinoma(HCC)comprises 75%-85%of liver cancers[2].The abysmal statistic is partly contributed by the fact that only 30%-40%of all patients are diagnosed at early stages that are amenable to potentially curative treatments[3].For over a decade,the availability of new agents,such as lenvatinib-and sorafenib-based targeted therapy,has significantly improved the outcome of patients with advanced HCC,prolonging the median overall survival(OS)from 4-8 months to 10-15 months[4,5].However,the therapeutic options for advanced HCC are still limited,and the prognosis is poor.展开更多
文摘With the expansion of vaccination programs,the policy of terminating nonpharmaceutical interventions for preventing the SARS-CoV-2 pandemic should become more flexible.The current study investigated the clinical and economic outcomes of intervention policies combining nonpharmaceutical interventions and vaccination programs for dealing with the SARS-CoV-2 pandemic.An agent-based transmission model was adopted that describes how a SARS-CoV-2 virus spreads in the populations of China.The model inputs were derived from the literature and expert opinion.The following intervention policies were simulated:no intervention,strict nonpharmaceutical interventions,and nonpharmaceutical interventions for workplace,community,school and home gradually terminated by combining vaccination programs for specified age groups(vaccination age in years:20-60,20-70,20-80,≥20,≥10 and whole population).Cumulative infections and deaths in one calendar year,costs and quality-adjusted life years(QALYs)were measured.When the vaccination program was taken up in at least the≥20 years age group in all populations,nonpharmaceutical interventions for workplace and community settings could be gradually terminated because the cumulative number of infections was<100 per 100,000 persons.Further ending nonpharmaceutical interventions in school and home settings could not meet the target even when the vaccination program had been taken up in all populations.When cumulative deaths were used as the endpoint,nonpharmaceutical interventions in workplace,community and school settings could be gradually terminated.Vaccine efficacy and coverage have substantial impacts.Terminating nonpharmaceutical interventions in workplace settings could produce the lowest cost when vaccination programs are taken up at least in the≥10 years age group;this method dominates most intervention strategies due to its lower costs and higher QALYs.According to our findings,nonpharmaceutical interventions might be gradually terminated in Chinese settings.
文摘Dear Editor,Liver cancer is the third leading cause of cancer deaths worldwide and accounted for 8.9%of all neoplasms,as shown by the Global Burden of Disease Study 2017[1].Hepatocellular carcinoma(HCC)comprises 75%-85%of liver cancers[2].The abysmal statistic is partly contributed by the fact that only 30%-40%of all patients are diagnosed at early stages that are amenable to potentially curative treatments[3].For over a decade,the availability of new agents,such as lenvatinib-and sorafenib-based targeted therapy,has significantly improved the outcome of patients with advanced HCC,prolonging the median overall survival(OS)from 4-8 months to 10-15 months[4,5].However,the therapeutic options for advanced HCC are still limited,and the prognosis is poor.
